PRKN and lung cancer: Loss of encoding Parkin (PARK2) increases the expression of proinflammatory factors as well as nuclear NF‐kB, suggesting a role of PARK2 loss in inflammation, and PARK2 deficiency promotes genomic instability and cell transformation, so PARK 2 might have a suppressor role in the development of COPD and lung cancer.20